Cargando…

Prognostic value of AIB1 and EIF5A2 in intravesical recurrence after surgery for upper tract urothelial carcinoma

OBJECTIVES: The aim of this study was to investigate the prognostic effect of amplified in AIB1 and EIF5A2 expression on postoperative intravesical recurrence for upper urinary tract urothelial carcinoma (UTUC) and improve postoperative risk stratification and prediction of intravesical chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yong, Wei, Jinhuan, Fang, Yong, Chen, Zhenhua, Cen, Junjie, Feng, Zihao, Lu, Jun, Liang, Yanping, Luo, Junhang, Chen, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298448/
https://www.ncbi.nlm.nih.gov/pubmed/30588104
http://dx.doi.org/10.2147/CMAR.S185392
_version_ 1783381318548062208
author Huang, Yong
Wei, Jinhuan
Fang, Yong
Chen, Zhenhua
Cen, Junjie
Feng, Zihao
Lu, Jun
Liang, Yanping
Luo, Junhang
Chen, Wei
author_facet Huang, Yong
Wei, Jinhuan
Fang, Yong
Chen, Zhenhua
Cen, Junjie
Feng, Zihao
Lu, Jun
Liang, Yanping
Luo, Junhang
Chen, Wei
author_sort Huang, Yong
collection PubMed
description OBJECTIVES: The aim of this study was to investigate the prognostic effect of amplified in AIB1 and EIF5A2 expression on postoperative intravesical recurrence for upper urinary tract urothelial carcinoma (UTUC) and improve postoperative risk stratification and prediction of intravesical chemotherapy benefit. MATERIALS AND METHODS: We evaluated immunohistochemical expression of AIB1 and EIF5A2 in 109 UTUC patients to determine the predictive significance in intravesical recurrence. A prognostic model was developed based on univariate and multivariate analyses. RESULTS: Intravesical recurrence occurred in 18 out of the 109 (16.5%) patients during the follow-up period. Significant associations of high expression of AIB1 and EIF5A2 with shortened bladder recurrence interval (median: 24 months vs 46 months, P=0.021; 28 months vs 39 months, P=0.002) were demonstrated. In different subsets of UTUC patients, high expression of AIB1 was a prognostic indicator in high grade (P=0.006) and pT2–4 (P=0.007), and high expression of EIF5A2 for high grade (P=0.014), pT2–4 (P=0.002) and pN0 (P=0.009). Moreover, in multivariate analysis, AIB1 and EIF5A2 expression (P=0.034 and 0.022, respectively) together with pN stage (P=0.009) provided significant independent predictors for intravesical recurrence after surgery for UTUC. Surgical approach with radical nephroureterectomy (RNU) was an informative factor toward good oncologic outcomes for intravesical recurrence (P=0.056). Based on a prognostic model with these factors, patients with UTUC were classified into the low-risk group and the high-risk group. In a subset analysis, the patients in the high-risk group were found to have a favorable response to intravesical chemotherapy (P=0.047). A nomogram based on the multivariate analysis was developed to predict intravesical recurrence accurately and guide postoperative intravesical instillations. The concordance index (c-index) of this model was 0.806. CONCLUSION: High expression of AIB1 and EIF5A2 were independent predictors for intravesical recurrence after RNU and might be able to predict which patients benefit from postoperative intravesical chemotherapy.
format Online
Article
Text
id pubmed-6298448
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62984482018-12-26 Prognostic value of AIB1 and EIF5A2 in intravesical recurrence after surgery for upper tract urothelial carcinoma Huang, Yong Wei, Jinhuan Fang, Yong Chen, Zhenhua Cen, Junjie Feng, Zihao Lu, Jun Liang, Yanping Luo, Junhang Chen, Wei Cancer Manag Res Original Research OBJECTIVES: The aim of this study was to investigate the prognostic effect of amplified in AIB1 and EIF5A2 expression on postoperative intravesical recurrence for upper urinary tract urothelial carcinoma (UTUC) and improve postoperative risk stratification and prediction of intravesical chemotherapy benefit. MATERIALS AND METHODS: We evaluated immunohistochemical expression of AIB1 and EIF5A2 in 109 UTUC patients to determine the predictive significance in intravesical recurrence. A prognostic model was developed based on univariate and multivariate analyses. RESULTS: Intravesical recurrence occurred in 18 out of the 109 (16.5%) patients during the follow-up period. Significant associations of high expression of AIB1 and EIF5A2 with shortened bladder recurrence interval (median: 24 months vs 46 months, P=0.021; 28 months vs 39 months, P=0.002) were demonstrated. In different subsets of UTUC patients, high expression of AIB1 was a prognostic indicator in high grade (P=0.006) and pT2–4 (P=0.007), and high expression of EIF5A2 for high grade (P=0.014), pT2–4 (P=0.002) and pN0 (P=0.009). Moreover, in multivariate analysis, AIB1 and EIF5A2 expression (P=0.034 and 0.022, respectively) together with pN stage (P=0.009) provided significant independent predictors for intravesical recurrence after surgery for UTUC. Surgical approach with radical nephroureterectomy (RNU) was an informative factor toward good oncologic outcomes for intravesical recurrence (P=0.056). Based on a prognostic model with these factors, patients with UTUC were classified into the low-risk group and the high-risk group. In a subset analysis, the patients in the high-risk group were found to have a favorable response to intravesical chemotherapy (P=0.047). A nomogram based on the multivariate analysis was developed to predict intravesical recurrence accurately and guide postoperative intravesical instillations. The concordance index (c-index) of this model was 0.806. CONCLUSION: High expression of AIB1 and EIF5A2 were independent predictors for intravesical recurrence after RNU and might be able to predict which patients benefit from postoperative intravesical chemotherapy. Dove Medical Press 2018-12-14 /pmc/articles/PMC6298448/ /pubmed/30588104 http://dx.doi.org/10.2147/CMAR.S185392 Text en © 2018 Huang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Huang, Yong
Wei, Jinhuan
Fang, Yong
Chen, Zhenhua
Cen, Junjie
Feng, Zihao
Lu, Jun
Liang, Yanping
Luo, Junhang
Chen, Wei
Prognostic value of AIB1 and EIF5A2 in intravesical recurrence after surgery for upper tract urothelial carcinoma
title Prognostic value of AIB1 and EIF5A2 in intravesical recurrence after surgery for upper tract urothelial carcinoma
title_full Prognostic value of AIB1 and EIF5A2 in intravesical recurrence after surgery for upper tract urothelial carcinoma
title_fullStr Prognostic value of AIB1 and EIF5A2 in intravesical recurrence after surgery for upper tract urothelial carcinoma
title_full_unstemmed Prognostic value of AIB1 and EIF5A2 in intravesical recurrence after surgery for upper tract urothelial carcinoma
title_short Prognostic value of AIB1 and EIF5A2 in intravesical recurrence after surgery for upper tract urothelial carcinoma
title_sort prognostic value of aib1 and eif5a2 in intravesical recurrence after surgery for upper tract urothelial carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298448/
https://www.ncbi.nlm.nih.gov/pubmed/30588104
http://dx.doi.org/10.2147/CMAR.S185392
work_keys_str_mv AT huangyong prognosticvalueofaib1andeif5a2inintravesicalrecurrenceaftersurgeryforuppertracturothelialcarcinoma
AT weijinhuan prognosticvalueofaib1andeif5a2inintravesicalrecurrenceaftersurgeryforuppertracturothelialcarcinoma
AT fangyong prognosticvalueofaib1andeif5a2inintravesicalrecurrenceaftersurgeryforuppertracturothelialcarcinoma
AT chenzhenhua prognosticvalueofaib1andeif5a2inintravesicalrecurrenceaftersurgeryforuppertracturothelialcarcinoma
AT cenjunjie prognosticvalueofaib1andeif5a2inintravesicalrecurrenceaftersurgeryforuppertracturothelialcarcinoma
AT fengzihao prognosticvalueofaib1andeif5a2inintravesicalrecurrenceaftersurgeryforuppertracturothelialcarcinoma
AT lujun prognosticvalueofaib1andeif5a2inintravesicalrecurrenceaftersurgeryforuppertracturothelialcarcinoma
AT liangyanping prognosticvalueofaib1andeif5a2inintravesicalrecurrenceaftersurgeryforuppertracturothelialcarcinoma
AT luojunhang prognosticvalueofaib1andeif5a2inintravesicalrecurrenceaftersurgeryforuppertracturothelialcarcinoma
AT chenwei prognosticvalueofaib1andeif5a2inintravesicalrecurrenceaftersurgeryforuppertracturothelialcarcinoma